www.tickerreport.com ·
Glaukos Nysegkos Director Gilbert Kliman Sells 5000 Shares
Topic context
This topic has been covered 273913 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInsider sale by a director of Glaukos (NYSE:GKOS), a medical device company focused on glaucoma treatments. The sale is a routine insider transaction with no direct commercial mechanism affecting product prices, supply chains, or margins. No scarcity, demand shock, or regulatory change is indicated. The impact is limited to potential signaling about management's view, but no concrete commercial channel is triggered.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Director Gilbert Kliman sold 5,000 shares of Glaukos (NYSE:GKOS) at $140.76 on May 14, 2026.
- Post-sale, Kliman holds 35,528 shares, a 12.34% decrease in ownership.
- Glaukos shares traded at $142.43 on May 18, 2026, with market cap $8.37B.
- Glaukos reported quarterly revenue of $150.57M, beating estimates, with negative EPS ($0.18).
- Institutional ownership is 99.04%.
Related stories
economictimes.indiatimes.com
IPO Investors Brace for 73 Lock in Expiries Worth 34 Billion in Three Months Will Your Portfolio Be Impacted
fool.com
Canaan Can Q1 2026 Earnings Transcript
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
zerohedge.com